CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin
P. K. Reville, I. N. Sheikh, A. Choi, E. Dai, J. Henderson, X. Li, E. Rojas, C. C. Le, C. Okwuchi, M. Devonish, R. Carrio, N. Pate, K. Malley, D. Bangari, J.-A. Givigan, , M. R. Green
The paper identifies dysfunctional CD8 CAR T-cells in rrLBCL tumors and shows that pegenzileukin mitigates this dysfunction, improving CAR T-cell responses.
bioRxiv · Aug 28, 2023 · PreprintImmunology